Abstract
Open Label Extension (OLE) of Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS) (P3.2-048)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have